Biomatik

Executive Summary

Biomatik, founded in 2002 and based in Wilmington, US, is a private biotechnology company that supplies research reagents and custom production services to the global life sciences community. The company offers a broad catalog of over 10,000 products, including ELISA kits, antibodies, proteins, and biochemicals, alongside custom gene, peptide, protein, and antibody services. Biomatik emphasizes quality, affordability, and reliability, serving more than 10,000 scientists worldwide. As a key supplier in the life sciences tools market, Biomatik benefits from steady demand for research consumables and custom services. The company's private status and lack of disclosed financials or funding rounds make it challenging to assess valuation or growth trajectory precisely. However, its long-standing presence and comprehensive product portfolio position it as a reliable partner in the competitive reagents market. Biomatik's ability to maintain customer loyalty and adapt to evolving research needs will be critical for sustained growth.

Upcoming Catalysts (preview)

• Q3 2026Launch of New High-Sensitivity ELISA Kits70% success
• Q4 2026Expansion of Custom Antibody Services into New Therapeutic Areas60% success
• Q1 2027Strategic Partnership with Academic Research Consortium50% success